Telesis Bio (Telesis Bio) Debt-to-Equity : 1.16 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Debt-to-Equity?

Telesis Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.82 Mil. Telesis Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $32.56 Mil. Telesis Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $29.54 Mil. Telesis Bio's debt to equity for the quarter that ended in Dec. 2023 was 1.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Telesis Bio's Debt-to-Equity or its related term are showing as below:

TBIO' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.64 Med: 0.19 Max: 1.16
Current: 1.16

During the past 5 years, the highest Debt-to-Equity Ratio of Telesis Bio was 1.16. The lowest was -0.64. And the median was 0.19.

TBIO's Debt-to-Equity is ranked worse than
90.27% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs TBIO: 1.16

Telesis Bio Debt-to-Equity Historical Data

The historical data trend for Telesis Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Debt-to-Equity Chart

Telesis Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.64

-0.33

0.19

0.46

1.16

Telesis Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.46	1.14	0.88	1.07	1.16

Competitive Comparison of Telesis Bio's Debt-to-Equity

For the Medical Devices subindustry, Telesis Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telesis Bio's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Telesis Bio's Debt-to-Equity falls into.

Telesis Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Telesis Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.822	+	32.558)	/	29.538
	=	1.16

Telesis Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.822	+	32.558)	/	29.538
	=	1.16

Telesis Bio (NAS:TBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Telesis Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Telesis Bio (Telesis Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121

Website

https://www.telesisbio.com

Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.

Executives

Gregory J. Herrema	director	355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers	10 percent owner	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p.	10 percent owner	1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc	10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider	director, 10 percent owner	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister	director, 10 percent owner	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler	officer: Chief Legal Officer	C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson	officer: Chief Technology Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson	director, 10 percent owner, officer: President & CEO	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser	officer: Chief Operating Officer	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814